50-49-7

• 常用中文名：米帕明
• 常用英文名：3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
• CAS号：50-49-7
• 分子式：C₁₉H₂₄N₂
• 分子量：280.40700
• 相关类别： 原料药 神经系统用药 抗抑郁、躁狂药
• 发布时间：2018-06-21 19:42:30
• 更新时间：2024-01-02 17:46:40
• 丙咪嗪是一种口服活性叔胺三环抗抑郁剂。丙咪嗪是一种具有抗肿瘤活性的Fancin1抑制剂。丙咪嗪刺激U-87MG胶质瘤细胞自噬并诱导HL-60细胞凋亡。丙咪嗪具有神经保护和免疫调节作用[1][2][3][4]。

名称

• 中文名: 米帕明
• 英文名: imipramine
• 中文别名: 丙咪嗪; 丙米嗪
• 英文别名: Berkomine; Dimipressin; EINECS 200-042-1; Antideprin; Nelipramin; [14C]-Imipramine; Intalpram; [3H]-Imipramine; Tofranil; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; Melipramine; Imidobenzyle; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Melipramin

物化性质

• 密度: 1.041g/cm3
• 沸点: 403.1ºC at 760mmHg
• 熔点: 174°C
• 分子式: C₁₉H₂₄N₂
• 分子量: 280.40700
• 闪点: 179.7ºC
• 精确质量: 280.19400
• PSA: 6.48000
• LogP: 3.94000
• 折射率: 1.574
• 储存条件:

  本品密封避光干燥保存。

• 分子结构:

  1、 摩尔折射率：88.92

  2、 摩尔体积（cm³/mol）：269.2

  3、 等张比容（90.2K）：677.5

  4、 表面张力（dyne/cm）：40.1

  5、 极化率（10-24cm3）：35.25

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:0

  3.氢键受体数量:2

  4.可旋转化学键数量:4

  5.互变异构体数量:无

  6.拓扑分子极性表面积6.5

  7.重原子数量:21

  8.表面电荷:0

  9.复杂度:291

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：常用其盐酸盐。为白色结晶性粉末

  2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：未确定

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC, 5.2 kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25 ºC）：未确定

  12. 饱和蒸气压（kPa,60 ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：易溶于水，遇水渐变黄红色

生物活性

• 描述: 丙咪嗪是一种口服活性叔胺三环抗抑郁剂。丙咪嗪是一种具有抗肿瘤活性的Fancin1抑制剂。丙咪嗪刺激U-87MG胶质瘤细胞自噬并诱导HL-60细胞凋亡。丙咪嗪具有神经保护和免疫调节作用[1][2][3][4]。
• 相关类别:
  信号通路 >> 细胞凋亡 >> 细胞凋亡
  研究领域 >> 癌症
  信号通路 >> 自噬 >> 自噬
  研究领域 >> 炎症/免疫
  研究领域 >> 神经疾病
• 靶点:

  Fascin1, Autophagy, Apoptosis[1][2][3]

• 体外研究: 丙咪嗪(0.5-300μM,3天)抑制HCT-116细胞活力[1]。丙咪嗪(20μM)抑制细胞迁移(7小时)和侵袭(48小时)[1]。丙咪嗪(50μM,0-240分钟)抑制U-87MG胶质瘤细胞中的PI3K/Akt/mTOR信号通路[2]。丙咪嗪(60μM,24小时)刺激U-87MG胶质瘤细胞自噬[2]。丙咪嗪(80μM,24小时)诱导HL-60细胞凋亡[3]。细胞活力测定[1]细胞系：DLD-1、HCT-116和SW-480浓度：0.5-300μM培养时间：3天结果：抑制细胞活力和HCT-117比DLD-2和SW-480更敏感。细胞迁移测定[1]细胞系：DLD-1、HCT-116和SW-480浓度： 结果：在所有受试细胞系中产生显著的迁移抑制。细胞侵袭试验[1]细胞系：HCT-116浓度：20μM孵育时间：48 结果：通过基质凝胶抑制细胞侵袭。Western Blot分析[2]细胞系：U-87MG浓度：50μM孵育时间：0、15、30、60、120和240分钟结果：显著抑制Akt(Ser473)和mTOR(Ser2481)的磷酸化,呈时间依赖性。还去磷酸化p70 S6K,mTOR的下游靶点。细胞自噬实验[2]细胞系：U-87MG浓度：60μM孵育时间：24小时结果：通过LC3在U-87MG胶质瘤细胞中的重新分布刺激自噬的诱导。凋亡分析[3]细胞系：HL-60浓度：80μM孵育时间：24小时结果：诱导细胞凋亡。
• 体内研究: 丙咪嗪(20 mg/kg,i.p.或15 mg/kg p.o.；每天24天)减弱神经炎症信号,逆转应激诱导的小鼠社交回避[4]。动物模型：雄性C57BL/6小鼠(6-8周龄)遭受RSD(重复社交失败)和HCC(家庭笼对照)[4]剂量：20 mg/kg或15 mg/kg给药：腹腔注射或口服,每天24天结果：逆转RSD诱导的社交回避行为,显著增加相互作用时间,显著降低脑小胶质细胞中应激诱导的IL-6 mRNA水平。
• 参考文献:

  [1]. Alburquerque-González B, et al. New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Exp Mol Med. 2020 Feb;52(2):281-292.

  [2]. Jeon SH, et al. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011 Sep 23;413(2):311-7.

  [3]. Xia Z, et al. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47.

  [4]. Ramirez K, et al. Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav Immun. 2015 May;46:212-20.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : HO1575000 CHEMICAL NAME : 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro- CAS REGISTRY NUMBER : 50-49-7 BEILSTEIN REFERENCE NO. : 0256892 LAST UPDATED : 199712 DATA ITEMS CITED : 62 MOLECULAR FORMULA : C19-H24-N2 MOLECULAR WEIGHT : 280.45 WISWESSER LINE NOTATION : T C676 BN&T&J B3N1&1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 71428 ug/kg/10D-I TOXIC EFFECTS : Behavioral - rigidity (including catalepsy) Skin and Appendages - sweating Nutritional and Gross Metabolic - body temperature increase TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 150 mg/kg TOXIC EFFECTS : Behavioral - coma Cardiac - other changes Vascular - BP lowering not characterized in autonomic section TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 71 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Cardiac - change in rate Endocrine - changes in luteinizing hormone TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 2 mg/kg/1D TOXIC EFFECTS : Lungs, Thorax, or Respiration - other changes TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 30 mg/kg TOXIC EFFECTS : Behavioral - hallucinations, distorted perceptions Behavioral - changes in motor activity (specific assay) Behavioral - coma TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 40 mg/kg TOXIC EFFECTS : Behavioral - hallucinations, distorted perceptions Behavioral - changes in motor activity (specific assay) Behavioral - coma TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 3 mg/kg/32H-I TOXIC EFFECTS : Skin and Appendages - photosensitivity (after systemic exposure) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 30 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Behavioral - ataxia TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 35 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Cardiac - other changes Lungs, Thorax, or Respiration - dyspnea TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 450 mg/kg TOXIC EFFECTS : Skin and Appendages - dermatitis, irritative (after systemic exposure) TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 40 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 5357 ug/kg/5D-I TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in REM sleep (human) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 8 mg/kg/3D-I TOXIC EFFECTS : Behavioral - excitement TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 250 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - changes in motor activity (specific assay) Nutritional and Gross Metabolic - body temperature decrease TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 79 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 250 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 9300 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 188 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - changes in motor activity (specific assay) Nutritional and Gross Metabolic - body temperature decrease TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 51600 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 195 ug/kg TOXIC EFFECTS : Behavioral - wakefulness Nutritional and Gross Metabolic - body temperature increase TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 21 mg/kg TOXIC EFFECTS : Autonomic Nervous System - parasympatholytic Behavioral - wakefulness Behavioral - changes in motor activity (specific assay) TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 107 mg/kg TOXIC EFFECTS : Autonomic Nervous System - smooth muscle relaxant (mechanism undefined, spasmolytic) TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 45 mg/kg TOXIC EFFECTS : Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 20 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 385 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 18 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 350 mg/kg TOXIC EFFECTS : Behavioral - anticonvulsant TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 455 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3600 mg/kg/4W-I TOXIC EFFECTS : Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 5760 mg/kg/22W-I TOXIC EFFECTS : Cardiac - EKG changes not diagnostic of specified effects Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 75 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 600 mg/kg SEX/DURATION : male 60 day(s) pre-mating female 60 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 378 mg/kg SEX/DURATION : lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 165 mg/kg SEX/DURATION : female 14 day(s) pre-mating female 1-19 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 40 mg/kg SEX/DURATION : female 14-21 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 210 mg/kg SEX/DURATION : female 21 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 18-21 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - biochemical and metabolic TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 130 mg/kg SEX/DURATION : female 8-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 65 mg/kg SEX/DURATION : female 8-20 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 175 mg/kg SEX/DURATION : female 7-13 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 87500 ug/kg SEX/DURATION : female 7-13 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 188 mg/kg SEX/DURATION : male 5 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraplacental DOSE : 80 ug/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraplacental DOSE : 80 ug/kg SEX/DURATION : female 15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 390 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 55 mg/kg SEX/DURATION : female 6-16 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 255 mg/kg SEX/DURATION : female 1-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : DNA inhibition TYPE OF TEST : Cytogenetic analysis TYPE OF TEST : Micronucleus test MUTATION DATA TEST SYSTEM : Rodent - mouse DOSE/DURATION : 188 mg/kg/5D (Intermittent) REFERENCE : IMSCE2 IRCS Medical Science. (Lancaster, UK) V.12-14, 1984-86. For publisher information, see MSCREJ. Volume(issue)/page/year: 14,1129,1986 *** REVIEWS *** TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 8,690,1974 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 1(1),93,1971 TOXICOLOGY REVIEW CLCHAU Clinical Chemistry (Winston-Salem, NC). (American Assoc. for Clinical Chemistry, 1725 K St., NW, Washington, DC 20006) V.1- 1955- Volume(issue)/page/year: 19,361,1973 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW FNSCA6 Forensic Science. (Lausanne, Switzerland) V.1-11, 1972-78. For pub lisher information, see FSINDR. Volume(issue)/page/year: 2,67,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 2,403,1969 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4727 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 103 (estimated) No. of Female Employees: 52 (estimated)

安全

• 海关编码: 2933990090

合成路线

494-19-9 109-54-6 ~% 50-49-7

文献：LUPIN LIMITED Patent: WO2009/47796 A1, 2009 ; Location in patent: Page/Page column 5 ;

6829-98-7 ~96% 50-49-7

文献：Gowda, Narendra B.; Rao, Gopal Krishna; Ramakrishna, Ramesha A. Tetrahedron Letters, 2010 , vol. 51, # 43 p. 5690 - 5693

876124-39-9 ~81% 50-49-7

文献：Ram, Siya; Ehrenkaufer, Richard E. Tetrahedron Letters, 1985 , vol. 26, # 44 p. 5367 - 5370

50-47-5 124-38-9 ~81% 50-49-7

文献：Li, Yuehui; Sorribes, Ivan; Yan, Tao; Junge, Kathrin; Beller, Matthias Angewandte Chemie - International Edition, 2013 , vol. 52, # 46 p. 12156 - 12160 Angew. Chem., 2013 , vol. 125, # 46 p. 12378 - 12382,5

50-47-5 ~% 50-49-7

文献：Ram, Siya; Ehrenkaufer, Richard E. Tetrahedron Letters, 1985 , vol. 26, # 44 p. 5367 - 5370

494-19-9 ~% 50-49-7

文献：Schindler; Haeflinger Helvetica Chimica Acta, 1954 , vol. 37, p. 472,481

58-28-6 ~% 50-49-7

文献：Ram, Siya; Spicer, Leonard D. Synthetic Communications, 1989 , vol. 19, # 20 p. 3561 - 3572

50-47-5 124-38-9 79-22-1 ~% 50-49-7

文献：Ram, Siya; Ehrenkaufer, Richard E. Tetrahedron Letters, 1985 , vol. 26, # 44 p. 5367 - 5370

上下游产品

上游产品  8
494-19-9 109-54-6 6829-98-7 876124-39-9
50-47-5 124-38-9 58-28-6 79-22-1
下游产品  5
50-47-5 6829-98-7 10075-24-8 796-28-1
303-70-8

制备

由邻硝基甲苯经缩合、还原得2，2′-氨基联苄与1-氯-3-二甲氨基丙烷缩合、成盐制得。

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%